Multidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa.
The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB.
Table of Contents
|1 Introduction and Overview of the Workshop||1-10|
|2 The Challenges and Opportunities for the BRICS Countries to Lead||11-22|
|3 Catching Up with the Microbe||23-30|
|4 Drug-Resistant TB in China||31-44|
|5 Experiences with MDR TB in Other Countries||45-54|
|6 Drug-Resistant Tuberculosis in Pediatric Populations||55-62|
|7 Global Perspectives on Transmission and Infection Control||63-78|
|8 Rapid Diagnostic Technologies: Status and Limitations||79-90|
|9 Addressing Diagnosis and Treatment Across the Spectrum of Drug Resistance||91-108|
|10 Developing and Strengthening the Drug Supply Chain for Drug-Resistant TB||109-118|
|11 Embracing a New Vision for Research||119-128|
|12 What Will Be Required to Achieve Zero Deaths from TB?||129-136|
|13 Creating an Evidence-Based Blueprint for Action||137-142|
|Appendix A: Workshop Agenda||151-170|
|Appendix B: Participant Biographies||171-196|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
Click here to obtain permission forThe Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS: Challenges and Opportunities: Summary of a Joint Workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences...